Canton Strategic Holdings (CNTN) Times Interest Earned (2021 - 2025)
Canton Strategic Holdings (CNTN) reported Times Interest Earned of -$576.07 for Q4 2025, up 88.55% on a YoY basis from -$305.52 in Q4 2024, and down 165.47% quarter-over-quarter from -$217.0 in Q3 2025.
Canton Strategic Holdings (CNTN) Times Interest Earned (2021 - 2025) Analysis & Trends
Canton Strategic Holdings has reported Times Interest Earned for 5 years, with the latest figure at -$576.07 in Q4 2025.
- For the quarter ending Q4 2025, Times Interest Earned rose 88.55% year-over-year to -$576.07; the trailing twelve-month figure through Mar 2026 stood at -$2171.4 (down 200.83% YoY), and the FY2025 full-year result was -$311.93, up 65.58% from the prior year.
- Times Interest Earned for Q4 2025 stood at -$576.07, down from -$217.0 in the prior quarter.
- The five-year high for Times Interest Earned was $201.74 in Q4 2022, with the low at -$7150.2 in Q4 2023.
- Historically, Times Interest Earned has averaged -$942.5 across 5 years, with a median of -$331.73 in 2025.
- Annual changes were most pronounced in 2022 — Times Interest Earned soared 51332.86% — and 2023, when it plunged 52267.26%.
- Canton Strategic Holdings' Times Interest Earned stood at -$0.39 in 2021, then soared by 51332.86% to $201.74 in 2022, then tumbled by 3644.24% to -$7150.2 in 2023, then gained by 29.63% to -$5031.2 in 2024, then jumped by 88.55% to -$576.07 in 2025.
- The last three Times Interest Earned figures came in at -$576.07 (Q4 2025), -$217.0 (Q3 2025), and -$300.46 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 3.58 |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 11.50 |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -258.33 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 547.67 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 11.79 |
| 10 | Canton Strategic Holdings | 699.97 Mn | 658.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -576.07 |
| Sep 30, 2025 | -217.00 |
| Jun 30, 2025 | -300.46 |
| Mar 31, 2025 | -300.63 |
| Dec 31, 2024 | -5,031.23 |
| Sep 30, 2024 | -1,284.67 |
| Jun 30, 2024 | -454.95 |
| Mar 31, 2024 | -499.43 |
| Dec 31, 2023 | -7,150.16 |
| Sep 30, 2023 | -527.77 |
| Jun 30, 2023 | -362.84 |
| Mar 31, 2023 | -442.23 |
| Dec 31, 2022 | 201.74 |
| Mar 31, 2022 | -0.84 |
| Dec 31, 2021 | -0.39 |
| Sep 30, 2021 | -2.29 |
| Jun 30, 2021 | -5.81 |
| Mar 31, 2021 | -9.90 |